Component
Brain-volume loss in progressive multiple sclerosis
Brain-volume loss in progressive multiple sclerosis. Species, exposure and limitations are retained in each linked claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Whole-brain and deep-gray volumes appeared more stable with ALA, but increased T2 lesion volume complicated interpretation.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/ala-research/41397213.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7fbea8d712bb6bea0dd8b7cfde3133b06d70a6eb881917767f4385f61c8d27ba", "start_char": 0, "end_char": 3010, "text_sha256": "7fbea8d712bb6bea0dd8b7cfde3133b06d70a6eb881917767f4385f61c8d27ba"}
- experimental_model
- Phase 2 randomized placebo-controlled progressive-MS trial; online December 2025, 2026 issue
- exposure
- Oral ALA 1200 mg/day for 24 months
- limitations
- Primary timed-walking result was null; imaging interpretation complicated by T2 lesion volume and differential discontinuation.
- nutrient_topic
- Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. · Lipoic acid
- organism
- Human
- plain_language
- Changes on scans need to be understood alongside lesions and clinical function.
- primary_references
- [ala-p41397213] Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41397213/ DOI: 10.1212/wnl.0000000000214454
- tissue_or_cell_type
- 115 participants, 54 ALA and 61 placebo
Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17) · lines 1274–1285
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Phase 2 randomized placebo-controlled progressive-MS trial; online December 2025, 2026 issue · source_derived_draft · unverified_draft
### ala-ms-phase2-imaging Whole-brain and deep-gray volumes appeared more stable with ALA, but increased T2 lesion volume complicated interpretation. Condition category: normal nutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: Changes on scans need to be understood alongside lesions and clinical function. organism: Human tissue_or_cell_type: 115 participants, 54 ALA and 61 placebo experimental_model: Phase 2 randomized placebo-controlled progressive-MS trial; online December 2025, 2026 issue limitations: Primary timed-walking result was null; imaging interpretation complicated by T2 lesion volume and differential discontinuation. exposure: Oral ALA 1200 mg/day for 24 months evidence_span: {"source_cache": "artifacts/ala-research/41397213.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7fbea8d712bb6bea0dd8b7cfde3133b06d70a6eb881917767f4385f61c8d27ba", "start_char": 0, "end_char": 3010, "text_sha256": "7fbea8d712bb6bea0dd8b7cfde3133b06d70a6eb881917767f4385f61c8d27ba"} [ala-p41397213] Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41397213/ DOI: 10.1212/wnl.0000000000214454
Complete structured claim and evidenceThe pilot found less annualized brain-volume loss with ALA than placebo, approximately 0.21% versus 0.65%.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/ala-research/28680916.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "fc584ca455d8a40e4ce91513974752b282425a74267d5b1d45db6275a51c2f5d", "start_char": 0, "end_char": 1904, "text_sha256": "fc584ca455d8a40e4ce91513974752b282425a74267d5b1d45db6275a51c2f5d"}
- experimental_model
- Two-year randomized placebo-controlled progressive-MS pilot
- exposure
- Oral lipoic acid 1200 mg/day
- limitations
- Small imaging-focused trial; brain volume is a surrogate and the walking comparison was not statistically significant.
- nutrient_topic
- Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. · Lipoic acid
- organism
- Human
- plain_language
- The imaging result favored treatment in this small study.
- primary_references
- [ala-p28680916] Lipoic acid in secondary progressive MS: A randomized controlled pilot trial. (2017). https://pubmed.ncbi.nlm.nih.gov/28680916/ DOI: 10.1212/nxi.0000000000000374
- tissue_or_cell_type
- 51 randomized participants with secondary progressive multiple sclerosis
Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17) · lines 1235–1246
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Two-year randomized placebo-controlled progressive-MS pilot · source_derived_draft · unverified_draft
### ala-ms-pilot-atrophy The pilot found less annualized brain-volume loss with ALA than placebo, approximately 0.21% versus 0.65%. Condition category: normal nutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: The imaging result favored treatment in this small study. organism: Human tissue_or_cell_type: 51 randomized participants with secondary progressive multiple sclerosis experimental_model: Two-year randomized placebo-controlled progressive-MS pilot limitations: Small imaging-focused trial; brain volume is a surrogate and the walking comparison was not statistically significant. exposure: Oral lipoic acid 1200 mg/day evidence_span: {"source_cache": "artifacts/ala-research/28680916.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "fc584ca455d8a40e4ce91513974752b282425a74267d5b1d45db6275a51c2f5d", "start_char": 0, "end_char": 1904, "text_sha256": "fc584ca455d8a40e4ce91513974752b282425a74267d5b1d45db6275a51c2f5d"} [ala-p28680916] Lipoic acid in secondary progressive MS: A randomized controlled pilot trial. (2017). https://pubmed.ncbi.nlm.nih.gov/28680916/ DOI: 10.1212/nxi.0000000000000374
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.